Portfolio

  • CHOPharmaInc.

    CHO Pharma Inc.

    - Find More -
  • SinewPharmaInc.

    Sinew Pharma Inc.

    - Find More -
  • StemCyteInc.

    StemCyte Inc.

    - Find More -
  • TetantiAgriBiotechInc.

    Tetanti AgriBiotech Inc.

    - Find More -
  • IridiumMedicalTechnologyCo.,Ltd.

    Iridium Medical Technology Co., Ltd.

    - Find More -
  • EyeYonMedicalLtd.

    EyeYon Medical Ltd.

    - Find More -
  • KendallCapitalPartners

    Kendall Capital Partners

    - Find More -
  • BilayerTherapeutics

    Bilayer Therapeutics

    - Find More -
  • ImmunAddInc.

    ImmunAdd Inc.

    - Find More -
  • RejuvenateBioInc.

    Rejuvenate Bio Inc.

    - Find More -
  • Syncell(Taiwan)Inc

    Syncell (Taiwan) Inc

    - Find More -
Close

CHO Pharma Inc.

Listed on TPEx Emerging Stock Board on September 27th, 2017 (TPEx : 6586)

Diamond Biofund provided us timely support with their exceptional team and valuable experience.

- President, Chung-Yi Wu, Ph.D -

In fact, like most biotech companies around the world that have pioneered new fields in the past decade, CHO Pharma has had a difficult time in the process.

Diamond Biofund’s excellent team and its successful experience in coaching companies has always provided timely assistance at critical moments, allowing me, who was originally focused on academic research but not familiar with the industry, to quickly identify a development blueprint that would allow CHO Pharma to play in the World Cup. This is the biggest difference between Diamond Biofund and most of the biomedical venture capitalists who only contribute capital. We believe that we will soon achieve our vision of becoming a global glycogen technology leader in biotechnology pharmaceuticals through continued support from Diamond Biofund.

CHOPharmaInc.

Introduction

CHO Pharma Co., Ltd. was established in March 2013 and holds an exclusive license for glycoscience-related patented technologies from Academia Sinica, including cancer vaccines, novel antibody drugs, glycan microarrays, and other related glycoscience patents. The company focuses on developing new drugs and disease diagnostic products.

Through its proprietary CHOptimax™ technology platform, CHO Pharma has successfully developed CHO-H01, the world’s first glyco-engineered biobetter drug. The company is now further expanding the applications of the CHOptimax™ platform in new drug development. Its research focuses include glyco-engineered biobetter drugs, antibody-drug conjugates with specific glycosylation sites, and novel vaccines.

Close

Sinew Pharma Inc.

Diamond Biofund is the nutrient and cultivator to the biotech startups

- Chairman and President, MD, PhD.,  Kai-Min Chu, Sinew Pharma -

Mr. Hu, Shih once said, " As you sow, so will you reap." This is an apt description of the biotech venture capital industry. In addition to a large amount of capital injection, biotech venture capitals devote more resources than the general industry, including upgrading technology and business strategies, enabling the biotechnology industry to thrive. Diamond Biofund is the nourisher and cultivator of new biotech ventures. From the start-up stage of Sinew Pharma all the way to the capital market, Diamond Biofund has always given Sinew the strongest support. In the future, Sinew will uphold the goal of solving unmet clinical needs and leading Sinew to the world.

SinewPharmaInc.

Introduction

Sinew Pharma was founded in June 2014 with the goal of developing innovative drugs to address important unmet medical needs. The company is currently focused on two major disease areas: 1) Metabolic dysfunction–associated steatohepatitis (MASH) and its associated conditions, such as liver cirrhosis and liver cancer. 2) Acetaminophen-induced hepatotoxicity and severe liver injury.

Driven by the demands in these disease areas, Sinew Pharma is developing a novel drug for MASH and the world's first new acetaminophen with high liver safety. By addressing these critical health challenges, SINEW aspires to become a globally leading pharmaceutical company.

Current pipeline includes six products, two of which are dedicated to MASH treatment, three aim to address liver toxicity issues arising from the widely used painkiller acetaminophen and its combinations, and one serves as an antidote for acetaminophen overdose.

Related News

Close

StemCyte Inc.

Diamond is not just an investor, but a partner.

- TY Lee, Ph.D, CEO -

I have worked with Diamond for more thank 8 years. Diamnod isn't interested for a short investment.
They are trying to build a collbration and parntership. Diamond brings a deep understanding of markets and technology that is invaluable. 
They are unique in being able to recognize the transformation potential of very early and unproven scientific project, and capital to bring those science to market. 
 

StemCyteInc.

Introduction

StemCyte is an international biopharmaceutical company dedicated to expanding the applications of cord blood storage and cell therapy. Founded in the United States in 1997, the company has established a strong presence in Taiwan and India. To date, StemCyte has built a public cord blood bank with over 36,000 units, making it one of the largest in scale globally, with unparalleled racial diversity and superior quality. It is also among the few biotechnology companies that operate both public and private cord blood banks.

Over the past 20 years, StemCyte has provided more than 2,300 cord blood units to over 350 transplant centers worldwide, supporting the treatment of various diseases. In November 2024, the company achieved a historic milestone by becoming the world’s first private enterprise to obtain FDA approval for a cord blood biologics license.

Additionally, StemCyte collaborates with leading medical teams both domestically and internationally to advance cell therapy technologies. The company is actively developing stem cell-based treatments using RegeneCyte for conditions such as long COVID and acute ischemic stroke. These therapies have demonstrated breakthrough progress in clinical trials, and StemCyte remains committed to expanding its research into multiple therapeutic applications.

Related News

Close

Tetanti AgriBiotech Inc.

Diamond Biofund “honors the way of Nature and benefits all beings”

- Dr. Chiu-Chung Young, Academician of Academia Sinica & National Chair Professor President, -

Diamond Biofund aims at identifying innovative biotechnologies in the medical and agricultural realm that can truly impact the well-being of human and the environment.

Diamond Biofund has been a key and valued partner in assisting TTT’s transition from the academic to the industry by bringing the precise and appropriate personnel and resources to the company. With the same eco-friendly vision and sustainable support, TTT is confident to achieve our novel technology’s potential values in the worldwide market.

TetantiAgriBiotechInc.

Introduction

Led by Academia Sinica Fellow, Yang, Chiu-Chung, Tetanti AgriBiotech has developed a rapid treatment technology using enzymes instead of microorganisms with thirty years of research results, and hopes to use this innovative knowledge technology in agricultural biotechnology to solve the current problems faced by the industry. Dr. Yang, Chiu-Chung holds a Ph.D. in Agronomy and Soil Science from the University of Hawaii. He is a pioneer in the field of organic fertilizers and soil microorganisms in Taiwan and was awarded the honor of Academia Sinica Fellow. The core TTT® technology uses targeted enzymes combined with equipment to convert organic waste into organic fertilizer in less than three hours. The research and development team of our founder, Academia Sinica Fellow, Yang, Chiu-Chung, has more than 8,000 strains and 2,500 species of functional bacteria as the source of target enzymes to provide customized enzyme combinations for different organic wastes of our customers. this threshold allows Tetanti to stand out as the leader in the field of organic waste management.

TTT® technology is efficient and cost effective, it greatly improves the maturization process of organic matter over 100 folds and can reduce pollution and increase product safety. The production process solves the odor, waste water, large area demand and time-consuming problems that are normally associated with traditional composting.

Tetanti was awarded “Taiwan’s 10 Coolest Technology Innovation Team” in 2019 and was interviewed by Discovery Channel in 2020, entitled “Taiwan Revealed: Agricultural Technology“. Tetanti will “Think Globally, Act Locally”, and we will stand firm in the circular economy trend. In response to the stringent environmental regulations and carbon emissions issues around the world, TTT® Technology will play an important key role in making agricultural sustainability no longer just a slogan!

Related News

Close

Iridium Medical Technology Co., Ltd.

Introduction

Iridium Medical Technology Company (IMTC) is an innovative neuron-electronic interface company, and the first to develop a high-acuity spherical bionic retina HARP4k. HARP4k, IMTC’s contact-lens-shaped wireless retinal prosthesis for retinal blindness caused by Retinitis Pigmentosa (RP) and Age-related Macular Degeneration (AMD), is a 30µm-thick packaged wireless implant with integrated camera chip, convolutional image processor and a high-density 4,000-microelectrode array interfacing to the retinal neurons. HARP4k supports the acuity needed for recognizing faces and objects, reading big-print books (font size > 14 pt.), and navigating through life.

Iridium Medical Technology Company (IMTC) has developed a high-definition spherical bionic retina for patients who have lost their vision due to retinal diseases. This bionic retina has been productized and entered human clinical trials. By leveraging Taiwan’s strengths in electronics and medical technology, IMTC aims to create a world-class Class III implantable medical device, positioning Taiwan’s high-end medical technology to compete in the global market.

Close

EyeYon Medical Ltd.

Diamond BioFund is a true example of “smart- money”

- Nahum Ferera/ CEO & Co Founder -

Diamond BioFund is a true example of “smart- money”. I am very honored to partner with a VC that understand the life-science industry, the changing environment and the multicultural differences. Diamond Biofund is also long lasting partner that was interested in seeing the company growing and succeeding to bring a true value to humankind.

 

EyeYonMedicalLtd.

Introduction

EyeYon Medical is an Israel-based medical device startup that develops innovative medical devices for the treatment of the cornea. EyeYon Medical has developed two therapeutic materials: Hyper-CL and EndoArt. Hyper-CL (High Permeability Contact Lens) is an effective non-surgical treatment for corneal edema. It is made of highly permeable contact lenses. They are disposable contact lenses and need to be replaced every two weeks. The product’s efficacy has been proven through clinical studies, is CE marked and FDA approved, and has been approved for sale in the European and US markets. EndoArt is an artificial retina replacement solution developed by EyeYon Medical that replaces the damaged endothelial layer of the eye with an artificial endothelial layer. The procedure is minimally invasive and seamless, requiring only a very small incision to insert the artificial layer. The product has already obtained the EU CE mark and received FDA approval for human clinical trials.

Related News

Close

Kendall Capital Partners

Introduction

Kendall Capital Partners focuses on early-stage investments in the field of biotechnology and medical care. It is a Boston-based venture capital fund composed of an investment team with business incubation experience.

Close

Bilayer Therapeutics

Introduction

Bilayer Therapeutics is a development-stage company co-founded in 2020 by a team of world-renowned drug development and delivery experts and gastroenterologists to stimulate the body’s innate mechanisms for regulating constipation and diarrhea. With a naturally occurring bile acid (chenodeoxycholate or CDC) delivered via proprietary bilayer tablet technology, the company is developing innovative treatments for Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation and other conditions of the colon.

CDC activates both established mechanisms of action for treating constipation: fluid flow and motility in the colon. By using CDC, Bilayer Therapeutics aims to offer more effective treatments for chronic constipation that will cause fewer side effects for patients.

Close

ImmunAdd Inc.

Introduction

Founded in 2022, ImmunAdd, Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation. ImmunAdd develops next generation saponin adjuvants and uses them as the basis for new combinations of adjuvants and adjuvanted vaccines to improve the efficacy and durability of vaccines.

Close

Rejuvenate Bio Inc.

Introduction

Rejuvenate Bio is a gene therapy company focused on treating chronic diseases based upon its breakthrough technology developed at the Wyss Institute of Harvard University. Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to patients suffering from chronic conditions. The company is developing a pipeline of therapies with applications in cardiac and metabolic diseases.

 

Related News

Close

Syncell (Taiwan) Inc

Introduction

SYNCELL was officially spun off from Academia Sinica in 2020 and continues to productize and commercialize the Microscoop technology platform. SYNCELL’s Microscoop spatial proteomics technology can turn a microscope into a “Microscoop” - the world’s first in-cell “pickable” microscope that applies an AI algorithm to selectively identify proteins and nucleic acids from a specified subcellular location.

Related News

  • OriginalBioMedicalsCo.,Ltd.

    Original BioMedicals Co., Ltd.

    - Find More -
  • OnenessBiotechCo.,Ltd.

    Oneness Biotech Co., Ltd.

    - Find More -
  • EnimmuneCorp.

    Enimmune Corp.

    - Find More -
  • 3DGlobalBiotech

    3D Global Biotech

    - Find More -
  • IOPtima

    IOPtima

    - Find More -
  • FountainBiopharma

    Fountain Biopharma

    - Find More -
Close

Original BioMedicals Co., Ltd.

Introduction

Original BioMedicals (OBM) has two main technologies : one is Chelating-Complex Micelle (CCM), composed of polyethylene glycol micelle with a metal moiety at the center which interacts – chelates-with blocking copolymers to form reversible bonds. CCM prolongs the half-life of the drug and can be tuned, by changing the diameters of the micelles, to modify the distribution of the micelle-drug complex in the body. These formulation modifications also increase their effective half-life while reducing potentially adverse effects. Another one is Trigger Release Technology, further utilizes the functions of the chelating agent within the micelle and allows for a controlled release rate and focused release location of drug. TRT creates innovative strategies for use of currently approved drugs that are safer and more effective than traditional formulations. The key to TRT is the ability to release drug by reversing the metal, drug interaction within CCM using common metal chelators delivered to specific site in the body.

OBM's vision is to using a collaborative research and professional environment, bring creative scientists and clinicians together to create novel formulations and innovative drug products that will improve the health and lives of people both locally and globally. 

Close

Oneness Biotech Co., Ltd.

Listed on Mainboard of TPEx on September 23rd, 2011 (TPEx : 4743)

Introduction

Oneness Biotech was established in June 2008 and has been approved as a “New Drug Biotech” company by the government. In June 2011, Oneness received approval from Securities and Futures Bureau (FSC) to be listed on the stock market and started to be traded since September 23rd 2011 (ticker: 4743). Oneness acquired Fountain Biopharma Inc. in August 23rd 2019.
 

Oneness Biotech have strong R&D team and pipelines focusing on chronic dermatology and immunology with pipelines in first-in-class or best-in-class new drugs spanning from Phases I, II, III, to NDA/approval phases.

The diabetic foot ulcer drug, FESPIXON® cream is a first-in-class new drug to treat DFUs by regulating macrophages. Its international Phase 3 trial results and novel mechanism have been published on the JAMA Network Open. It has been demonstrated with superior efficacy to the standard of care and robust efficacy in the hard-to-heal ulcer subgroups. This new drug will have revolutionary impact on the future DFU management. FESPIXON® cream has been granted by Taiwan FDA in March 2021. To accelerate the entry into the global market, FESPIXON® cream is under NDA review in China. It has also been under multiple NDA submissions to the South East Asian health authorities while a second phase 3 study is being conducted in the US. Besides, to ensure the drug quality and supplies after the marketing authorization is obtained, Oneness has implemented GACP on the raw material for more than 12 years. A PIC/S GMP manufacturing plant for the API extraction and finish product has also been established in Nanchou, Pingtung in Taiwan with site registration certification and manufacturer’s license. This will be able to supply the APIs and drug product of FESPIXON® cream for the global market demand.

Oneness owns a full-human antibody library and a monoclonal antibody drug development platform, and masters the key technologies of new antibody drugs from R (research) to D (development). The R&D team have established multiple antibody technologies, including a fully-human antibody library, high-throughput antibody screening platform, anti-IgE (immunoglobulin E) antibody, and anti-IL6 (interleukin-6) antibody, non-clinical antibody functionality assay, stable and high-yield antibody-producing cell lines and other key technologies, with strong capability for first-class antibody new drugs. At present, FB825 and FB704A have been developed based on those proprietary technologies.

FB704A developed from the fully-human antibody library" technology platform, is a new anti-IL6 fully human antibody drug. The in vitro analysis and in vivo biological activities show that it can effectively inhibit the secretion of inflammatory cytokines by a variety of cells, inhibit the activity of the inflammatory hormone MCP-1 secreted by synovial membrane cells on the IL6-induced rheumatoid arthritis (RA) patients and also can tumor angiogenesis. FB704A has been greenlighted by the US FDA to proceed with a Ph2 clinical trial. FB825 (Anti-CεmX), a new anti-allergic antibody drug, has been completed various ex vivo, in vivo, clinical and safety studies. It is currently under two Ph2 trials for atopic dermatitis and allergic asthma. This new drug has been out-licensed to LEO Pharma, the medical dermatology leader. Oneness continues to work closely with the partner in order to maximize the development value.

OB318 is an anti-cancer new drug extracted from Antrodia cinnamomea and has been completed mass production and fermentation with more than 98% of its formulation quantitated. This ensures OB318 meet the threshold for the launch of the botanical new drugs with controllable drug quality according to the international regulations for botanical new drugs. It is currently under Taiwan and US IND for a Ph1 clinical trial.

With dedication into the research and development in botanical, small molecule, and antibody new drugs, Oneness continues to focus on chronic dermatology and immunology. Oneness strengthen the collaboration with the global pharmas based on our breakthrough innovation and science. Based in Taiwan, Oneness hope to connect the world with our new drug and make the contribution to the human health. 

Related News

Close

Enimmune Corp.

2018, September listed in TPEx (6564:TT)

 

 

EnimmuneCorp.

Introduction

ENIMMUNE’s main business activity is to conduct clinical trials of new drugs, develop sales outlets, and collaborate with research-based pharmaceutical companies to facilitate the commercialization of new drugs.
By forging an alliance within the ecosystem, ENIMMUNE integrate all sources to roll out new drugs efficiently.
The phased results of new drug development are also licensed to other manufacturers. In the future, ENIMMUNE plans to introduce technology to develop innovative new drugs.

Close

3D Global Biotech

2020, December listed in TPEx (6808:TT)

Diamond Biofund organizes various resources to reduce failure costs and risks

- - Ken Ou / Chairman - -

Diamond Biofund is a sustainable venture capital in the biotechnology field with great expertise and rich experience in industry investment. Starting from the seed stage of our company, Diamond organizes support and resources all the way from establishment and expansion stages to reduce costs and failure risk. 3D Global Biotech is currently working towards its target of going IPO . We look forward to supporting the company's operation and development through the Diamond Biofund and successfully achieving the company's milestones.

3DGlobalBiotech

Introduction

3D Global Biotech is a biotech company aiming to develop human reconstruction materials.
3D Global Biotech has developed two major categories of products based on cell culture systems, 3D printing technology, and bio-inks, including medical materials for the reconstruction of soft tissues and hard tissues. The soft tissue reconstruction products include biohydrogel ink and corneal epithelial reconstruction products...etc. The hard tissue reconstruction products are mainly orthopedic reconstruction, dental and jaw reconstruction, and cranial reconstruction products.
3D Global Biotech will develop a platform for the reconstruction of human tissues and organs with innovative and outstanding pioneering technology, and develop exclusive, customized and personalized high-end medical devices to fulfill its mission of professional research, service and care, respect for life and giving back to society.

Close

IOPtima

Diamond Biofund is one of the start-up investors of IOPtima, and I am proud to work with Diamond.

- - CEO, Ronen Castro, IOPtima - -

Diamond Biofund were one of the first investors in IOPTIMA and it was a real pleasure for me to work with them. The team at Diamond Biofund is extremely talented and professional. When they go into investing in a company, they understand the market, the competition and the potential well. Diamond Biofund plans strategically and long-term and has the patience and commitment to ensure the companies achieve the most success. Thanks to them, more investors joined the round and it was a great pride for me when we were able to generate a return on investment in a relatively short time. I will always appreciate their contribution to IOPtima and our current success.

IOPtima

Introduction

IOPtima Ltd. is an Israeli company that develops ophthalmic surgical equipment. Its product, IOPtimate, can transform complex and high-risk glaucoma surgery into a safe, concise, and precise new medical solution, and has the opportunity to replace the current standard surgical treatment, The product has obtained China CFDA certification in 2014, and has obtained the European CE marketing license.
China's Chengdu Kanghong Pharmaceutical acquired IOPtima in 2018, valued at US$56 million.

Close

Fountain Biopharma

Introduction

Fountain Biopharma owns the world's largest fully human antibody library. It is an international-level antibody new drug company that masters R (research) to D (development). It has built a number of "antibody technology platforms" to form a strong international new drug independent R&D innovation. Strength, including successful construction of fully human antibody library, antibody high-efficiency screening, anti-IgE (immunoglobulin), anti-IL6 (interleukin-6), glycosome homogenization, preclinical antibody functional verification, stable high-yield antibody Key technologies for the production of new antibody drugs such as cell lines. In order to strengthen the R&D pipelines and enhance the competitiveness for the international market, in 2019, it merged with Oneness Biotech; the two companies are complementary and mutually beneficial in terms of new drug R&D capabilities. The merger makes the R&D structure more complete, Not only has international-level new drugs that are closer to entering the market, but also has short, medium and long-term development of new autoimmune and tumor drug product lines and key platform technologies; through the merger of the two companies, it has integrated innovative drugs, high-end talents, new drug manufacturing, Analysis and identification, pharmacological research, toxicological research, pharmacokinetics, clinical trials and drug regulations and other important links, forming a strong R&D team lineup and new drug strength, will be more conducive to establishing international cooperation with large international research institutions and pharmaceutical companies, and enhance the global market. Competitiveness.

↑